Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85,300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0.
Markowitz J, Shamblott M, Brohl AS, Sarnaik AA, Eroglu Z, Khushalani NI, Dukes CW, Chamizo A, Bastawrous M, Garcia ET, Dehlawi A, Chen PL, De Aquino DB, Sondak VK, Tarhini AA, Kim Y, Lawman P, Pilon-Thomas S. Markowitz J, et al. Among authors: kim y. Mol Cancer Ther. 2024 Aug 1;23(8):1139-1143. doi: 10.1158/1535-7163.MCT-23-0652. Mol Cancer Ther. 2024. PMID: 38657233 Free PMC article. Clinical Trial.
Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation.
Sung H, Kanchi KL, Wang X, Hill KS, Messina JL, Lee JH, Kim Y, Dees ND, Ding L, Teer JK, Yang S, Sarnaik AA, Sondak VK, Mulé JJ, Wilson RK, Weber JS, Kim M. Sung H, et al. Among authors: kim m, kim y. Oncotarget. 2016 Apr 26;7(17):23885-96. doi: 10.18632/oncotarget.8127. Oncotarget. 2016. PMID: 26993606 Free PMC article.
Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, Naghavi AO, Kim S, Kim Y, Patel BG, Sarangkasiri S, Johnstone PA, Sahebjam S, Khushalani NI, Forsyth PA, Harrison LB, Yu M, Etame AB, Caudell JJ. Ahmed KA, et al. Among authors: kim s, kim y. Ann Oncol. 2016 Dec;27(12):2288-2294. doi: 10.1093/annonc/mdw417. Epub 2016 Sep 15. Ann Oncol. 2016. PMID: 27637745 Free PMC article.
Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough?
Perez MC, de Pinho FR, Holstein A, Oliver DE, Naqvi SMH, Kim Y, Messina JL, Burke E, Gonzalez RJ, Sarnaik AA, Cruse CW, Wuthrick EJ, Harrison LB, Sondak VK, Zager JS. Perez MC, et al. Among authors: kim y. Ann Surg Oncol. 2018 Oct;25(11):3334-3340. doi: 10.1245/s10434-018-6688-y. Epub 2018 Aug 2. Ann Surg Oncol. 2018. PMID: 30073600 Free PMC article.
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.
Hill KS, Roberts ER, Wang X, Marin E, Park TD, Son S, Ren Y, Fang B, Yoder S, Kim S, Wan L, Sarnaik AA, Koomen JM, Messina JL, Teer JK, Kim Y, Wu J, Chalfant CE, Kim M. Hill KS, et al. Among authors: kim s, kim m, kim y. Mol Cancer Res. 2019 Feb;17(2):583-593. doi: 10.1158/1541-7786.MCR-18-0777. Epub 2018 Oct 24. Mol Cancer Res. 2019. PMID: 30355677 Free PMC article.
Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma.
Eroglu Z, Eatrides J, Naqvi SMH, Kim Y, Rich J, Babacan NA, Brohl AS, Markowitz J, Sarnaik A, Zager J, Khushalani NI, Sondak VK, Messina J. Eroglu Z, et al. Among authors: kim y. Pigment Cell Melanoma Res. 2020 Jan;33(1):86-95. doi: 10.1111/pcmr.12813. Epub 2019 Sep 12. Pigment Cell Melanoma Res. 2020. PMID: 31329344 Free PMC article.
85,300 results
You have reached the last available page of results. Please see the User Guide for more information.